Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

Wilson-Poe, Adrianne R.; Smith, Tristin; Elliott, Michael R.; Kruger, Daniel J.; Boehnke, Kevin F.

doi:10.1001/jamanetworkopen.2023.47373

Cited by 6 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While cannabidiol (CBD) continues to be the dominant non-intoxicating cannabinoid of interest to both consumers and researchers, cannabigerol (CBG) has rapidly increased in popularity [2].…”

Section: Introductionmentioning

confidence: 99%

Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo- Controlled, Crossover, Field Trial

Cuttler,

Stueber,

Cooper

et al. 2024

Preprint

View full text Add to dashboard Cite

Cannabigerol (CBG) is a phytocannabinoid increasing in popularity, with preclinical research indicating it has anxiolytic and antidepressant effects. However, there are no published clinical trials to corroborate these findings in humans. The primary objective of this study was to examine acute effects of CBG on anxiety, stress, and mood. Secondary objectives were to examine whether CBG produces subjective drug effects or motor and cognitive impairments. A double-blind, placebo-controlled cross-over field trial was conducted with 34 healthy adult participants. Participants completed two sessions (with a one-week washout period) via Zoom. In each, they provided ratings of anxiety, stress, mood, and subjective drug effects prior to double-blind administration of 20mg hemp-derived CBG or placebo tincture (T0). These ratings were collected again after participants ingested the product and completed an online survey (T1), the Trier Social Stress Test (T2), a verbal memory test and the DRUID impairment app (T3). Relative to placebo, there was a significant main effect of CBG on overall reductions in anxiety as well as reductions in stress at T1. CBG also enhanced verbal memory relative to placebo. There was no evidence of subjective drug effects or impairment. CBG may represent a safe, novel option to manage stress and anxiety.

show abstract

Section: Introductionmentioning

confidence: 99%

Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo- Controlled, Crossover, Field Trial

Cuttler,

Stueber,

Cooper

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Producers are responding to this demand by isolating various minor phytocannabinoids and terpenes and marketing them with bold, but largely unsubstantiated, claims of their therapeutic potential. While cannabidiol (CBD) continues to be the dominant non-intoxicating cannabinoid of interest to both consumers and researchers, cannabigerol (CBG) has rapidly increased in popularity 2 .…”

Section: Introductionmentioning

confidence: 99%

Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial

Cuttler,

Stueber,

Cooper

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Cannabigerol (CBG) is a phytocannabinoid increasing in popularity, with preclinical research indicating it has anxiolytic and antidepressant effects. However, there are no published clinical trials to corroborate these findings in humans. The primary objective of this study was to examine acute effects of CBG on anxiety, stress, and mood. Secondary objectives were to examine whether CBG produces subjective drug effects or motor and cognitive impairments. A double-blind, placebo-controlled cross-over field trial was conducted with 34 healthy adult participants. Participants completed two sessions (with a one-week washout period) via Zoom. In each, they provided ratings of anxiety, stress, mood, and subjective drug effects prior to double-blind administration of 20 mg hemp-derived CBG or placebo tincture (T0). These ratings were collected again after participants ingested the product and completed an online survey (T1), the Trier Social Stress Test (T2), a verbal memory test and the DRUID impairment app (T3). Relative to placebo, there was a significant main effect of CBG on overall reductions in anxiety as well as reductions in stress at T1. CBG also enhanced verbal memory relative to placebo. There was no evidence of subjective drug effects or impairment. CBG may represent a novel option to reduce stress and anxiety in healthy adults.

show abstract

“…In recent years, North America has been reported to have the highest prevalence of past-year cannabis use compared to other sub-regions globally at 14.5% [ 4 ]. Of the emerging cannabinoids available, cannabidiol (CBD), a principal cannabinoid presumed to be non-euphoric and non-intoxicating, has the highest prevalence of past-year use [ 5 ]. Past-year CBD use was reported to be 26.1% in the United States and 16.2% in Canada [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC)

Lo,

Christiansen,

Strickland

et al. 2024

Neuropsychopharmacol.

View full text Add to dashboard Cite

Cannabidiol (CBD) is widely used and believed to be non-intoxicating, lacking acute performance effects (e.g., non-impairing). However, a synthesis of data has not evaluated this. This meta-analysis synthesized data from controlled human laboratory studies that evaluated if acute CBD use impairs performance. Performance on objective and subjective measures of cognitive and psychomotor function were used as markers for potential performance changes and impairment. Studies were identified through systematic database searches. Adult clinical trials measuring acute CBD effects (within 0–8 h of administration) were included. The primary outcome was the peak mean difference in performance measures between CBD and placebo. A secondary analysis utilizing delta-9-tetrahydrocannabinol (Δ9-THC) as a positive control for comparison to CBD was completed. Pooled Hedges’ g estimates were calculated using robust variance estimation (RVE) meta-regression. The omnibus RVE meta-analysis indicated a statistically significant, but small effect size (Hedge’s g < 0.2) for impaired performance following acute CBD consumption compared to placebo (N = 16 trials, Hedges’ g = 0.122, 95% CI: 0.023–0.221, p = 0.019). Measure type was a significant moderator with larger mean differences between CBD and placebo when subjective measures, specifically self-reported sedation, were used versus objective performance tasks (Hedges’ gSubjective = 0.288 versus Hedges’ gObjective = 0.048). Δ9-THC had a significantly greater magnitude of impairment compared to CBD (N = 8, Hedges’ g = 0.416, 95% CI: 0.017–0.816, p = 0.043). In summary, acute CBD consumption was associated with a small increase in subjective ratings of sedation, but no difference from placebo was observed across multiple domains of objectively assessed cognitive or psychomotor performance. These findings suggest that acute CBD alone is unlikely to significantly impair daily functioning or workplace performance.

show abstract

Past-Year Use Prevalence of Cannabidiol, Cannabigerol, Cannabinol, and Δ8-Tetrahydrocannabinol Among US Adults

Abstract: This survey study characterizes past-year use prevalence and factors associated with use of cannabidiol, cannabigerol, cannabinol, and Δ8-tetrahydrocannabinol among US adults.

Cited by 6 publications

References 5 publications

Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo- Controlled, Crossover, Field Trial

Acute Effects of Cannabigerol on Anxiety, Stress, and Mood: A Double-Blind, Placebo- Controlled, Crossover, Field Trial

Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial

Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC)

Contact Info

Product

Resources

About